Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

ClinicalTrials.gov ID: NCT02055274

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02055274. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to characterize the pharmacokinetics (PK) of LY03003 following multiple escalating intramuscular injections, as compared to Neupro patch and to evaluate the safety and tolerability and preliminary efficacy of multiple ascending dose (MAD) of LY03003 following intramuscular injections.

Study identification

NCT ID: NCT02055274
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Luye Pharma Group Ltd.; Industry
Enrollment: 39 participants

Conditions and interventions

Conditions

Parkinson's Disease

Interventions

LY03003 Drug
Neupro Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2013 (Type not available)
Primary completion: Aug 2015 (Actual)
Completion: Aug 2015 (Actual)
Last update posted: Oct 21, 2015

2013 – 2015

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Collaborative Neuroscience Network LLC	Long Beach	California	90806	—
Compass Research LLC	Orlando	Florida	32806	—
West Georgia Sleep Disorders Center and Neurology Associates	Douglasville	Georgia	30134	—
Quest Research Institute	Bingham Farms	Michigan	48025	—
PRA - CRI Lifetree	Marlton	New Jersey	08053	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02055274, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 21, 2015 · Synced Nov 14, 2026